AMLN Amylin Pharmaceuticals, Inc. (MM)

Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Illumina, Inc. (NASDAQ: ILMN) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).

Access to full reports can be found at:

www.ParagonReport.com/ILMN www.ParagonReport.com/AMLN

As larger companies reduce spending on research and development they are looking at smaller biotech companies to diversify their product lines. M&A allows bigger companies to acquire products and technology that are already proven in the market place, avoiding the many risks associated with research and development.

On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Illumina, Inc. announced that it will issue results for first quarter 2012 following the close of market on Monday, April 23, 2012. On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay Flatley, President and Chief Executive Officer; Christian Henry, Senior Vice President and General Manager, Genomic Solutions; and Marc Stapley, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Amylin Pharmaceuticals, Inc. will webcast its Quarterly Update Conference Call for the first quarter of 2012 on Thursday, April 26, 2012 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2012.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine